A randomized phase 2 clinical trial has been conducted to evaluate the use of quantitative ultrasound imaging in predicting response and guiding personalized neoadjuvant chemotherapy in breast cancer. The trial's results have been reported, although the specifics of the findings are not detailed in the available information. The study aimed to assess the effectiveness of quantitative ultrasound imaging in tailoring chemotherapy treatment for breast cancer patients.